Cutera : Company Overview Presentation - April 2024

A P R I L 2 0 2 4

Safe Harbor Statement

Forward-Looking Statements

This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential," "objective," "would," the negative of these terms, or and other similar expressions intended to identify statements about the future. Forward-looking statements speak only as of the date they are made and involve risks and uncertainties, many of which are beyond our control. Important factors could cause actual results to differ materially from those in the forward-looking statements, including, among others, the risks, uncertainties and factors set forth under "Risk Factors" in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera. Forward-looking statements speak only as of the date they are made. We assume no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Management bases all estimates as to events that may occur in the future upon their best judgment as of the date of this presentation. Whether or not such estimates may be achieved will depend upon us achieving our overall business objectives and the availability of funds. Actual results will vary from the estimates, and such variations may be material. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and for the market in which we operate are subject to a high degree of risk and uncertainty. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the market and our market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of our business.

Use of Non-GAAP Financial Measures

This presentation includes the non-GAAP financial measure of non-GAAP Operating Income, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). Non-GAAP Operating Income in this presentation represents earnings before interest, taxes, depreciation and amortization, stock-based compensation, executive and other non-recurring separation costs, enterprise resource planning system costs, non-recurring legal and litigation costs, Board of Director legal and advisory fees, and expenses related to the termination of a manufacturing agreement. Non- GAAP Operating Income is presented because we believe it is a useful indicator of operating performance. We use this financial measure as a measure of our Company's operating performance and for planning purposes, including financial projections. We believe this measure is useful to investors as supplemental information because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We believe non-GAAP Operating Income is useful to us and investors as a measure of comparative operating performance from period to period. Non-GAAP Operating Income is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that our Company's future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for our management's discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Non-GAAP Operating Income contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating non-GAAP Operating Income, you should be aware that in the future we may incur expenses that are the same or similar to some of the adjustments in this presentation. Our presentation of non-GAAP Operating Income should not be construed to imply that its future results will be unaffected by any such adjustments. We compensate for these limitations by primarily relying on our GAAP results in addition to using non-GAAP Operating Income on a supplemental basis. Our definition of this measure is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

2

A New Energy in Aesthetics

Mission	Vision
Improve lives through medical aesthetic	To be the premier
technologies that are driven by science	provider of medical
and powered through partnerships	aesthetic technologies

PICO Values

Passion

Innovation

Communication

Ownership

31. Source: Custom market insights 2023 Acne Treatment Market Size, Trends and Insights By Product Type report 1. Source: Custom market insights 2023 Acne Treatment Market Size, Trends and Insights By Product Type report

Shaping aesthetics & dermatology with innovation

Demographics powering	Decades of innovation =
solid market growth	technological leadership

$5B+ global market for foundational platforms benefitting from Millennials and men increasingly seeking treatment

Differentiated product platforms are advancing skin and body care globally

Launching first acne innovation in decades

Commercializing a durable solution for the treatment of acne - a $14B+ market1 in need of new treatment options

Organizational recalibration underway

New leadership with deep industry experience focused on operational excellence, right-sizing cost structure & proven strategies to unlock value

4 4	1. Source: Custom market insights 2023 Acne Treatment Market Size, Trends and Insights By Product Type report

Leadership with Track Records of Success

Deep aesthetics and med-tech expertise

Taylor Harris	Michael Karavitis	Stuart Drummond	Jeff Jones
CEO	CTO	Interim CFO	COO

Stephana Patton	Steve Kreider	Brent Hauser	TJ Huffman
Chief Legal	SVP, Global	President,	VP, NA Sales
Officer	Marketing	International

BOD members	Kevin Cameron	Taylor Harris	Sheila Hopkins	Nicholas Lewin	Keith Sullivan
Board Chairperson	Director	Director	Director	Director

5

Expanding Global Footprint

Clinically-Focused and Robust Sales Infrastructure

Direct Sales Distributors	40+

Countries

% Revenue1

EMEA

20K+

Devices shipped

APAC

66 Source: (1) As of 2023; source: company filings

North

America

Comprehensive Portfolio of Energy-basedSolutions for Aesthetic Providers & Dermatologists

Skin tightening Fat reduction Muscle sculpting

$2B+

Body contouring1

Skin revitalization Vascular Pigment Scar revision

Tattoo removal

5 % C A G R T O 2 0 2 7

$3B+

Face & skin revitalization1

5 % C A G R T O 2 0 2 7

$14B+ Acne2

7 % C A G R T O 2 0 3 2

Source: (1) Medical Insight, Inc. 2024 Global Aesthetic Market Study | 2. Custom market insights

7 2023 Acne Treatment Market Size, Trends and Insights By Product Type report

Well-Established, Robust Franchises Support Continued Innovation & Entry into Acne Vertical

Face & skin	Body		Acne
revitalization	contouring
AviClear®
SkinSuite excel® V & V+	TruBody	truSculpt®
Secret TM		truFlex TM

xeo®

Other

enlighten® excel® HR

8

Established Leader in

Professional Face & Skin

Revitalization Market

70%	~90%
of patients are bothered by	of pregnant women, 70% of
lines, wrinkles, skin texture,	adolescent females and 40% of
and / or discoloration1	adolescent males have stretch marks2

56%	40%
of consumers are considering	of active acne patients
treatments to help smooth	have scars3
wrinkles or tighten skin1

9	Sources: 1. American Society for Dermatologic Surgery. ASDS survey on dermatologic procedures. | 2. Karia, U. K., Padhiar, B. B., & Shah, B. J. (2016). Evaluation of Various Therapeutic Measures in Striae Rubra. Journal of cutaneous and aesthetic
surgery, 9(2), 101-105. | 3. Dréno, B., Tan, J., Kang, S., Rueda, M. J., Torres Lozada, V., Bettoli, V., & Layton, A. M. (2016). How People with Facial Acne Scars are Perceived in Society: an Online Survey. Dermatology and therapy, 6(2), 207-218.

Skin revitalization Skin resurfacing Pigmented lesions

Vascular lesions

Hair removal

10

Introducing xeo+®

Key Features

• Customizable, multi-application laser- and light- based modular, expandable platform
• Treats the industry's widest range of common non- surgical aesthetic concerns
• +20 years on the market​
• Features Cutera's legacy in Nd:YAG technology, Laser GenesisTM,​ and 3 IPL handpiece options
• High practice ROI​